Resources from the same session
LBA73 - Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
Presenter: Toni Choueiri
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA74 - Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Presenter: Brian Rini
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA75 - Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
Presenter: Lothar Bergmann
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Webcast
1959O - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)
Presenter: Dingwei Ye
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1690O - NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Presenter: Eric Jonasch
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1959O and 1690O
Presenter: Jonathan Rosenberg
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Webcast